Mitophagy Agonist
Undisclosed (Mitochondrial Dysfunction)
Pre-clinicalActive
Key Facts
About Capacity Bio
Capacity Bio is an early-stage biotech pioneering a novel approach to treating diseases linked to mitochondrial dysfunction by developing modulators of mitophagy. The company has secured $35 million in financing from top-tier investors like RA Capital and Insight Partners to advance its lead program toward clinical trials in 2024. With a dual operational presence in the US and Japan, Capacity Bio is leveraging a multi-modal strategy involving small molecules, peptides, and nanoparticles to enhance the clearance of damaged mitochondria and restore cellular health.
View full company profile